Private Advisor Group’s Arbutus Biopharma ABUS Stock Holding History

Private Advisor Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$53.4K	Buy	+11,164	New	+$53.8K	﹤0.01%	3042

Other funds holding ABUS

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Carrera Capital Advisors Troy, Michigan $705M AUM 12.86% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Private Advisor Group's ABUS Position: Q3 2026 in Review

Private Advisor Group opened a new position in Arbutus Biopharma (ABUS) in Q3 2026: 11,164 shares worth $53.4K. The stake represents ﹤0.01% of the portfolio and ranks #3042 among its holdings.

90 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

Private Advisor Group held 11,164 shares of Arbutus Biopharma worth $53.4K as of Q3 2026.
Arbutus Biopharma was a new Private Advisor Group position in Q3 2026.
Arbutus Biopharma made up ﹤0.01% of Private Advisor Group's portfolio in Q3 2026, its #3042 holding.
90 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Private Advisor Group's 13F filing for Q3 2026, filed 10 Nov 2026.